Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

IL0006290147
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG000HD3FM1
TEVA
Teva Pharmaceutical Industries Ltd
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: High-Tech-Biomed-Pharma · THEMEFOLIO: $HLTH
NAME
Teva Pharmaceutical Industries Ltd
ISIN
IL0006290147
TICKER
TEVA
MIC
XTAE
REUTERS
TEVA.TA
BLOOMBERG
TEVA IT
Fr., 18.09.2026       Teva
IL0006290147

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from a discrete choice experiment highlighting preferred healthcare provider (HCP) treatment attributes when selecting a VMAT2 inhibitor for the treatment of TD in older...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Teva
IL0006290147

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new real-world data evaluating treatment continuity, healthcare resource utilization (HCRU) and clinical outcomes among adults with schizophrenia and bipolar I disorder (BD-I) tr...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 18.09.2026       Teva
IL0006290147

PARSIPPANY, N.J., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new olanzapine LAI (TEV-'749) post hoc data from the pivotal SOLARIS Phase 3 trial as well as analyses supporting treatment switch strategies. The SOLARIS dat...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 16.09.2026       Teva
IL0006290147

PARSIPPANY, N.J., and TEL AVIV, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of LongActingImpact.com, a new educational website for healthcare providers (HCPs) with information to support informed treatment discussions and...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Teva
IL0006290147

Teva begins direct trading of its ordinary shares on the NYSE under TEVA, completing its ADS transition and advancing its Pivot to Growth strategy....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 14.09.2026       Teva
IL0006290147

Instrument ID [34869360] (TEVA - IL0006290147) suspended...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 10.09.2026       Teva
IL0006290147

TEL AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the “Notes”). Teva expects to use the net proceeds from the offering, together with cash on hand, (i) to fund t...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 07.09.2026       Teva
IL0006290147

TEL AVIV, Israel, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today its intention to issue senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“Teva Finance II”) intends to offer EUR-denominated Senior Notes (the “Euro N...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 04.09.2026       Teva
IL0006290147

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 02.09.2026       Teva
IL0006290147

Teva reports positive Phase 2a results for Teva-discovered TEV ’408, showing significant prevention of gluten-induced intestinal damage in celiac disease....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 01.09.2026       Teva
IL0006290147

TEL AVIV, Israel, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at three upcoming investor conferences in September as follows:...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 31.08.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreem...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 28.08.2026       Teva
IL0006290147

Teva Pharmaceuticals proposes acquiring BXCL501, expanding its neuroscience portfolio with a novel agitation treatment under FDA review...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 29.07.2026       Teva
IL0006290147

Q2 2026 Highlights:...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 09.07.2026       Teva
IL0006290147

TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polph...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Teva
IL0006290147

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the “Investors” page on its website....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Teva
IL0006290147

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 18.06.2026       Teva
IL0006290147

TEL AVIV, Israel and PARSIPPANY, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2026 financial results on Wednesday, July 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 10.06.2026       Teva
IL0006290147

TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva’s acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Ne...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 08.06.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, June 08, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with AUSTEDO® and AUSTEDO XR®. The new findings, drawn fr...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 05.06.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, June 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the first and only real-world, decentralized study evaluating the patient- and caregiver-reported quality of life impacts of Huntington’s diseas...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Teva
IL0006290147

PARSIPPANY, N.J., and TEL AVIV, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on Monday, June 8, 2026. The fireside chat will begin at 8:00 A.M....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 21.05.2026       Teva
IL0006290147

TEL AVIV, Israel and PARIS, May 21, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Medincell (Euronext: MEDCL), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for olanzapine long-ac...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Teva
IL0006290147

For an accessible version of this Press Release, please visit www.tevapharm.com ...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Teva
IL0006290147

PARSIPPANY, N.J. and CHICAGO, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Emalex Biosciences (“Emalex”) today announced a definitive agreement for Teva to acquire Emalex, including its lead asset, ecopipam. The positive Phase 3 data of ecopipam in chil...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 15.04.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia and their care partners with c...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 14.04.2026       Teva
IL0006290147

Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Teva
IL0006290147

TEL AVIV, Israël et PARSIPPANY, New Jersey, 30 mars 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE et TASE : TEVA) a annoncé aujourd’hui trois progrès importants pour son portefeuille de médicaments biosimilaires, qui témoignent de la dynamique soutenue de sa stratégie « Pivot to Growth ». La Food and Drug Administration...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Teva
IL0006290147

TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demonstrating continued momentum in the advancement of its Pivot to Growth strategy. The United States (U.S.) Food and Drug Administration (FDA) has appro...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Teva
IL0006290147

TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Do., 19.03.2026       Teva
IL0006290147

TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcas...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 03.03.2026       Teva
IL0006290147

PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences (“BXLS”) today announced a $400 million strategic funding agreement spread across four years to support the continued clinical d...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 24.02.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the upcoming investor conferences in March as follows:...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extende...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 17.02.2026       Teva
IL0006290147

Teva will hold an investor call and live webcast today, Tuesday, February 17, 2026, at 8:00 a.m. ET to discuss these data....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 28.01.2026       Teva
IL0006290147

Q4 and FY 2025 Highlights:...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 27.01.2026       Teva
IL0006290147

PARSIPPANY, N.J., and TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a partnership with actor, comedian and advocate, Will Forte, to increase awareness of Huntington’s disease (HD). HD, a rare, progressive neurological disorde...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 14.01.2026       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the New England Journal of Medicine (NEJM) has published pivotal Phase 3 data on AJOVY, highlighting its efficacy and safety in children and adolescents...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
So., 11.01.2026       Teva
IL0006290147

Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
So., 11.01.2026       Teva
IL0006290147

PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Royalty Pharma plc (Nasdaq: RPRX), today announced a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-’408. IL-1...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mo., 05.01.2026       Teva
IL0006290147

TEL AVIV, Israel, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 24.12.2025       Teva
IL0006290147

TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva’s long-term issuer credit rating to ‘BB+’ from ‘BB’, with a stable outlook, and that Moody's Ratings Agency ("Moody's") affirmed Teva's B1a rating and revised Teva'...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 19.12.2025       Teva
IL0006290147

REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that t...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Teva
IL0006290147

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website....
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 12.12.2025       Teva
IL0006290147

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter 2025 financial results on Wednesday, January 28, 2026, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day,...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Teva
IL0006290147

PARSIPPANY, N.J. and TEL AVIV, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for olanzapine extended-release injectable suspension (TEV-'749)...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Mi., 26.11.2025       Teva
IL0006290147

TEL AVIV, Israël, 26 nov. 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, filiale de Teva Pharmaceutical Industries Ltd. (NYSE : et TASE : TEVA), annonce que la Commission européenne (CE) vient d’accorder des autorisations de mise en marché visant ses deux candidats biosimilaires au dénosumab, à savoir PONLIMSI, un biosimil...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Di., 25.11.2025       Teva
IL0006290147

TEL AVIV, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) announced that the European Commission (EC) has granted marketing authorizations for its two denosumab biosimilar candidates – PONLIMSI, a biosimilar to Prolia®1 and DEGEVMA, a bio...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 21.11.2025       Teva
IL0006290147

TEL AVIV, Israel, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and other members of executive management will present at three upcoming investor conferences in December as follows:...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink
Fr., 07.11.2025       Teva
IL0006290147

PARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets...
Zur Nachricht
Teva
Charts & Research Termsheets Terminal
Permalink